|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADGRG6 |
Gene summary for ADGRG6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADGRG6 | Gene ID | 57211 |
| Gene name | adhesion G protein-coupled receptor G6 | |
| Gene Alias | APG1 | |
| Cytomap | 6q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0003007 | UniProtAcc | Q86SQ4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57211 | ADGRG6 | NAFLD1 | Human | Liver | NAFLD | 9.15e-11 | 1.02e+00 | -0.04 |
| 57211 | ADGRG6 | S43 | Human | Liver | Cirrhotic | 4.66e-09 | -8.30e-02 | -0.0187 |
| 57211 | ADGRG6 | HCC1_Meng | Human | Liver | HCC | 1.02e-89 | -5.60e-02 | 0.0246 |
| 57211 | ADGRG6 | HCC2_Meng | Human | Liver | HCC | 3.22e-50 | 1.98e-01 | 0.0107 |
| 57211 | ADGRG6 | cirrhotic1 | Human | Liver | Cirrhotic | 5.43e-07 | -2.94e-01 | 0.0202 |
| 57211 | ADGRG6 | cirrhotic2 | Human | Liver | Cirrhotic | 2.74e-06 | -2.36e-01 | 0.0201 |
| 57211 | ADGRG6 | cirrhotic3 | Human | Liver | Cirrhotic | 4.38e-03 | -3.18e-01 | 0.0215 |
| 57211 | ADGRG6 | HCC2 | Human | Liver | HCC | 3.05e-06 | 3.26e+00 | 0.5341 |
| 57211 | ADGRG6 | HCC5 | Human | Liver | HCC | 5.01e-03 | 7.43e-01 | 0.4932 |
| 57211 | ADGRG6 | Pt13.a | Human | Liver | HCC | 6.25e-16 | -4.44e-01 | 0.021 |
| 57211 | ADGRG6 | Pt13.b | Human | Liver | HCC | 6.54e-08 | -4.44e-01 | 0.0251 |
| 57211 | ADGRG6 | Pt13.c | Human | Liver | HCC | 1.36e-04 | -4.44e-01 | 0.0076 |
| 57211 | ADGRG6 | Pt14.d | Human | Liver | HCC | 1.22e-16 | -4.44e-01 | 0.0143 |
| 57211 | ADGRG6 | S027 | Human | Liver | HCC | 2.34e-09 | 1.14e+00 | 0.2446 |
| 57211 | ADGRG6 | S028 | Human | Liver | HCC | 1.21e-24 | 1.21e+00 | 0.2503 |
| 57211 | ADGRG6 | S029 | Human | Liver | HCC | 3.07e-17 | 1.18e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0042063 | Liver | Cirrhotic | gliogenesis | 98/4634 | 301/18723 | 1.28e-03 | 8.60e-03 | 98 |
| GO:0010001 | Liver | Cirrhotic | glial cell differentiation | 75/4634 | 225/18723 | 2.24e-03 | 1.36e-02 | 75 |
| GO:0042552 | Liver | Cirrhotic | myelination | 46/4634 | 134/18723 | 8.04e-03 | 3.77e-02 | 46 |
| GO:0007272 | Liver | Cirrhotic | ensheathment of neurons | 46/4634 | 136/18723 | 1.08e-02 | 4.75e-02 | 46 |
| GO:0008366 | Liver | Cirrhotic | axon ensheathment | 46/4634 | 136/18723 | 1.08e-02 | 4.75e-02 | 46 |
| GO:00072721 | Liver | HCC | ensheathment of neurons | 72/7958 | 136/18723 | 8.87e-03 | 3.44e-02 | 72 |
| GO:00083661 | Liver | HCC | axon ensheathment | 72/7958 | 136/18723 | 8.87e-03 | 3.44e-02 | 72 |
| GO:00425521 | Liver | HCC | myelination | 71/7958 | 134/18723 | 9.08e-03 | 3.49e-02 | 71 |
| GO:00420631 | Liver | HCC | gliogenesis | 148/7958 | 301/18723 | 1.10e-02 | 4.07e-02 | 148 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADGRG6 | SNV | Missense_Mutation | c.1627N>A | p.Glu543Lys | p.E543K | Q86SQ4 | protein_coding | tolerated(0.56) | benign(0.047) | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| ADGRG6 | SNV | Missense_Mutation | novel | c.3113N>T | p.Ala1038Val | p.A1038V | Q86SQ4 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
| ADGRG6 | SNV | Missense_Mutation | c.1226G>A | p.Gly409Glu | p.G409E | Q86SQ4 | protein_coding | tolerated(0.08) | possibly_damaging(0.869) | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD | |
| ADGRG6 | SNV | Missense_Mutation | c.2254A>G | p.Thr752Ala | p.T752A | Q86SQ4 | protein_coding | tolerated(0.05) | possibly_damaging(0.539) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| ADGRG6 | insertion | Frame_Shift_Ins | novel | c.3114_3115insTTAAT | p.Met1039LeufsTer7 | p.M1039Lfs*7 | Q86SQ4 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| ADGRG6 | insertion | Frame_Shift_Ins | novel | c.1045_1046insTATCAGTAATAATAAG | p.Lys349IlefsTer8 | p.K349Ifs*8 | Q86SQ4 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ADGRG6 | SNV | Missense_Mutation | c.2932N>T | p.Gly978Cys | p.G978C | Q86SQ4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A0VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ADGRG6 | SNV | Missense_Mutation | c.809G>C | p.Arg270Thr | p.R270T | Q86SQ4 | protein_coding | tolerated(0.41) | benign(0.117) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ADGRG6 | SNV | Missense_Mutation | c.1078C>G | p.Leu360Val | p.L360V | Q86SQ4 | protein_coding | tolerated(0.07) | benign(0.227) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| ADGRG6 | SNV | Missense_Mutation | rs370831198 | c.1207N>A | p.Asp403Asn | p.D403N | Q86SQ4 | protein_coding | tolerated(0.35) | benign(0.005) | TCGA-ZJ-AAX4-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |